PRGO · Perrigo Company plc
$13.66
+0.52% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
5.7
Dividend yield
8.0%
Beta
0.60
Avg volume
3M
Employees
8K
Daily Change %
0.52%
5 Days Change
-3.89%
10 Days Change
-2.05%
30 Days Change
13.89%
60 Days Change
43.20%
Month to Day Change
-0.62%
Year to Day Change
10.29%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PRGO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-02-27
Latest call per bank · past 12 months
JP Morgan
Neutral$18.00
+32.5% vs priceJefferies
Hold$23.00
+69.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-02-27 | Canaccord Genuity | Maintains | Buy | $20.00 → $17.00 |
| 2025-12-15 | JP Morgan | Maintains | Neutral | $20.00 → $18.00 |
| 2025-11-06 | Canaccord Genuity | Maintains | Buy | $40.00 → $20.00 |
| 2025-11-06 | JP Morgan | Downgrade | Overweight → Neutral | $32.00 → $20.00 |
| 2025-10-27 | Jefferies | Maintains | Hold | $27.00 → $23.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.3% above the 50-day MA ($12.06).
- Price vs 200-day MA: Trading 16.8% above the 200-day MA ($11.70).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.83) and high ($21.06).
PRGO Price Chart
Loading chart for PRGO…
Fundamentals
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.